ENHERTU® (trastuzumab deruxtecan) Receives Time-Limited Reimbursement Recommendation from Canada's Drug Agency for Gastric Cancer
MISSISSAUGA, ON, May 23, 2025 /CNW/ - AstraZeneca (AZ) and Daiichi Sankyo (DS) are pleased to announce that Canada's Drug Agency (CDA, formerly CADTH) has issued a Time-Limited Reimbursement (TLR) recommendation – the first in gastric cancer – for ENHERTU® (trastuzumab deruxtecan) based on the unmet need of adult patients with unresectable, locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. Additionally, the pan-Canadian Pharmaceutical Alliance (pCPA), AstraZeneca, and Daiichi Sankyo have recently signed a Letter of Intent (LOI) through the recently introduced Temporary Access Process (pTAP). This step, alongside the CDA TLR processes, paves the way for jurisdictional reimbursement.
'As early participants in these innovative drug reimbursement processes, AstraZeneca and Daiichi Sankyo are pleased to accelerate access to innovative treatments for Canadian patients, particularly in areas of great unmet need, such as HER2+ gastric cancer,' says Gaby Bourbara, President, AstraZeneca Canada. 'The TLR/pTAP process is intended for a subset of medicines assessed with a very specific set of criteria, and we look forward to continuing to work with our partners within the drug reimbursement ecosystem to unlock additional mechanisms for accelerating access to more medicines in the future.'
It is estimated that these processes will make ENHERTU available to gastric cancer patients close to two years faster than traditional reimbursement pathways which would have required the completion and review of the Phase III DESTINY-Gastric04 study.
'Daiichi Sankyo and our partners at AstraZeneca are committed to ongoing collaboration with the HTA bodies to identify and leverage new ways to make medicines accessible to patients across the country as fast as possible following Health Canada approval,' says Fatih Yedikardeş, Country Manager, Daiichi Sankyo Canada.
For medications that show early promise and have been given conditional regulatory approval, the TLR and pTAP processes represent a path for accelerated access while ongoing confirmatory trials are in progress.1,2
Health Canada granted a Notice of Compliance with conditions (NOC/c) for ENHERTU (trastuzumab deruxtecan) on January 17, 2025, for the treatment of adult patients with unresectable, locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.3 The conditional approval was authorized based on results from DESTINY-Gastric024 and DESTINY-Gastric015 Phase II trials. The confirmatory Phase III trial, DESTINY-Gastric046 is currently underway and is a global, randomized, open-label, trial evaluating the efficacy and safety of trastuzumab deruxtecan (6.4 mg/kg) versus ramucirumab and paclitaxel in patients with HER2- positive (IHC 3+ or IHC 2+/ISH+) unresectable and/or metastatic gastric or GEJ adenocarcinoma with disease progression on or after a trastuzumab-containing regimen.
About Gastric Cancer
Gastric (stomach) cancer is the fifth most common cancer worldwide and the fourth leading cause of cancer mortality with a five-year survival rate of 7.5% for metastatic disease.7,8 In Canada, it is estimated that 4,200 people will be diagnosed, and 2,000 people will die from the disease this year.9
About ENHERTU
ENHERTU (trastuzumab deruxtecan) is a HER2-directed antibody-drug conjugate. Designed using Daiichi Sankyo's proprietary DXd antibody drug conjugate (ADC) technology, ENHERTU consists of a HER2 monoclonal antibody attached to a topoisomerase I inhibitor payload, an exatecan derivative, via a stable tetrapeptide-based cleavable linker.
About the Daiichi Sankyo and AstraZeneca Collaboration
Daiichi Sankyo Company, Limited (referred to as Daiichi Sankyo) and AstraZeneca entered into a global collaboration to jointly develop and commercialize ENHERTU in March 2019 and datopotamab deruxtecan (Dato-DXd) in July 2020, except in Japan where Daiichi Sankyo maintains exclusive rights for each ADC. Daiichi Sankyo is responsible for the manufacturing and supply of ENHERTU and datopotamab deruxtecan.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical business whose innovative medicines are used by millions of patients worldwide. The company's core areas of scientific focus are Oncology; Cardiovascular, Renal and Metabolic (CVRM); Rare Disease; Respiratory & Immunology; and Vaccine & Immune Therapies. In Canada, the company employs more than 2,400 people and recently announced a major expansion of its research footprint in Mississauga – including the expansion of its AstraZeneca R&D Hub and the creation of a new Alexion Development Hub for Rare Diseases. AstraZeneca was recently recognized as one of Canada's Top 100 Employers, one of Canada's Most Admired Corporate Cultures, and a Greater Toronto Top Employer.
AstraZeneca is committed to contributing to a more sustainable future for people, society and planet, taking important steps to help tackle some of the most pressing sustainability challenges globally – from climate and biodiversity loss, to health equity and health system resilience. AstraZeneca was one of the first seven companies globally to have its net zero targets verified by the Science-Based Targets initiative (SBTi) Corporate Net-Zero Standard. For more information, please visit the company's website at www.astrazeneca.ca.
About Daiichi Sankyo
Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose 'to contribute to the enrichment of quality of life around the world.' In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an 'Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.' For more information, please visit http://www.daiichi-sankyo.eu.
References
SOURCE AstraZeneca Canada Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
9 hours ago
- Business Upturn
The European Space Agency and Dassault Aviation paving the way for potential collaborations
PRESS RELEASE June 20, 2025 The European Space Agency and Dassault Aviation paving the way for potential collaborations ESA and Dassault Aviation have identified a mutual interest in developing a closer relationship to commonly foster technology development in areas such as LEO destinations and particularly around orbital vehicules. The European Space Agency (ESA) has signed a Letter of Intent (LoI) with Dassault Aviation, a French civilian and military aircraft manufacturer recognized worldwide for its excellence, underlying their common interest to develop a closer relationship. ESA, with its ambitious strategy for space exploration, Explore2040, is seeking innovative solutions for capabilities development to reach and return from Low Earth Orbit (LEO), Moon and Mars, and supports the advancement of selected critical enabling technologies to be used and demonstrated in particular in LEO, such as hypervelocity re-entry. Dassault Aviation, also a leader in aerospace engineering, is developing its space activities with a focus on the design of a reusable spaceplane based on lifting bodies shapes that bridge aeronautical and space technologies. Their interest in automated LEO platforms suitable for commercial and institutional markets, led them to develop a vehicle concept called ' Véhicule Orbital Réutilisable de Transport et d'Exploration (VORTEX) ', designed for research in space, transport of cargo to and from space stations, and a range of in-orbit services. This project is based on a considerable expertise in spaceplanes having participated in numerous programmes like Hermes, NASA X-38 Crew Rescue vehicle, ESA Intermediate eXperimental Vehicle (IXV) demonstrator, and Airborne Reusable Hypersonic Experimental Vehicle (VEHRA) concepts. ' Dassault Aviation's decades of expertise in aeronautical and space systems, perfectly position them to pioneer critical space technologies ', said Josef Aschbacher, Director General of the European Space Agency. ' With VORTEX, Dassault is contributing to strengthening European capacities and securing sovereign access to space in a strongly growing and competitive space sector. We look forward to combining our expertise and working hand-in-hand for a stronger Europe in space.' ' Our Vortex roadmap aims to strengthen Europe's essential sovereign capabilities and meet the new challenges of the space economy. This letter of intent is a perfect recognition of the complementary expertise of the European Space Agency and Dassault Aviation in the development of critical technologies and innovative space solutions, ' declared Eric Trappier, Chaiman and CEO of Dassault Aviation. As such, the signatories of the LoI, have identified a mutual interest in developing a closer relationship with the potential to commonly derisking critical technologies as well as to further explore the potential for collaboration in areas such as LEO destinations and particularly around orbital vehicules. As such, both foresee an interest to cooperate on a scaled down suborbital version of VORTEX, serving as a testbed, with a focus on, but not limited to: Designing, testing and qualifying key technologies and components. New materials and integration processes. Assessing the feasibility to include future payloads in case of the integration of a dedicated bay on the end-product. This joint work will be based on exchanging relevant information and conducting studies or preparatory activities, to help establish respective roles and responsibilities in the realisation of potential joint activities, leveraging on each side's capabilities. ' Europe benefits from a wide range of diverse and complementary skills. Enlarging the European industrial base is key for new opportunities arising in Space Exploration, aiming at more autonomy,' said Daniel Neuenschwander, Director of Human and Robotic Exploration at ESA. About the European Space Agency The European Space Agency (ESA) provides Europe's gateway to is an intergovernmental organisation, created in 1975, with the mission to shape the development of Europe's space capability and ensure that investment in space delivers benefits to the citizens of Europe and the world. ESA has 23 Member States: Austria, Belgium, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Luxembourg, the Netherlands, Norway, Poland, Portugal, Romania, Slovenia, Spain, Sweden, Switzerland and the United Kingdom. Latvia, Lithuania and Slovakia are Associate Members. ESA has established formal cooperation with other four Member States of the EU. Canada takes part in some ESA programmes under a Cooperation Agreement. By coordinating the financial and intellectual resources of its members, ESA can undertake programmes and activities far beyond the scope of any single European country. It is working in particular with the EU on advancing the Galileo and Copernicus programmes as well as with Eumetsat for the development of meteorological missions. Learn more about ESA at
Yahoo
9 hours ago
- Yahoo
Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics. Different than value or growth investors, momentum-oriented investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks. AstraZeneca plc, headquartered in London, UK, is one of the largest biopharmaceutical companies in the world. AstraZeneca was formed on Apr 6, 1999, through the merger of Sweden's Astra AB and UK's Zeneca Group plc. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include CVRM (cardiovascular, renal and metabolism), Respiratory & Immunology (R&I), Oncology, Rare Diseases, Vaccines and Other. AZN boasts a Momentum Style Score of B and VGM Score of A, and holds a Zacks Rank #3 (Hold) rating. Shares of Astrazeneca has seen some interesting price action recently; the stock is down 5.7% over the past one week and up 1.2% over the past four weeks. And in the last one-year period, AZN has lost 9.9%. As for the stock's trading volume, 3,618,926.50 shares on average were traded over the last 20 days. A company's earnings performance is important for momentum investors as well. For fiscal 2025, two analysts revised their earnings estimate higher in the last 60 days for AZN, while the Zacks Consensus Estimate has increased $0 to $4.49 per share. AZN also boasts an average earnings surprise of 4.2%. AZN should be on investors' short list because of its impressive earnings fundamentals, a good Zacks Rank, and strong Momentum and VGM Style Scores. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12 hours ago
- Yahoo
Leviathan Gold to acquire 100% interest in Botswanian copper and uranium assets
Leviathan Gold has signed a non-binding letter of intent (LoI) with Cura Exploration Botswana to acquire a 100% interest in a significant copper and uranium exploration portfolio in Botswana. This move comes through the acquisition of all issued and outstanding securities of Privco, which holds the prospecting licences in the region. Privco is currently party to share purchase agreements (SPA) for the purchase of all shares of the AfriMetals Entities, which possess the Central Project land package adjacent to MMG's Khoemacau deposits. These deposits boast substantial mineral resources and were acquired by MMG for $1.9bn (A$2.93bn) in 2023. The AfriMetals Entities also hold a comprehensive portfolio of uranium prospecting licences in Botswana. The Serule Uranium Project is located next to the Letlhakane Uranium Project, which Lotus Resources acquired in 2023. Recent drilling at Serule has indicated a mineralised zone more than 4km wide. Under the proposed terms, Leviathan Gold will issue 35,000,000 common shares and 5,500,000 share purchase warrants in exchange for Privco shares and warrants. The company will also assume the obligation to pay milestone payments to the sellers, potentially issuing up to an additional 16,500,000 Leviathan Shares. The proposed transaction is subject to the completion of due diligence within 60 days from the LoI and the finalisation of a definitive agreement. If completed, Privco's former shareholders would own approximately 35% of Leviathan Gold, or 38.5% if all warrants are exercised. The transaction is expected to be executed through a "three-cornered" amalgamation with a wholly owned subsidiary of Leviathan and is subject to restrictions and policies of the TSX Venture Exchange. Leviathan Gold president and CEO Luke Norman said: 'The proposed acquisition by Leviathan of Privco would result in Leviathan adding to its portfolio of mineral assets the highly strategic and yet under-explored Central Project directly adjoining MMG's world-class Khoemacau 'Cluster' of copper deposits on the Kalahari Copper Belt – with which Central appears to share important geophysical, structural and stratigraphic indicators – places Leviathan in pole position to make a major copper discovery in mining-friendly Botswana.' Under the terms of the SPAs, Privco must fulfil financial obligations that include not only the milestone payments but also a total cash payment of $2.2m. To date, Privco has already paid $390,000.01 of this amount to the sellers. Furthermore, Privco has spent C$93,000 on the creation of technical reports in compliance with National Instrument 43-101, which sets the disclosure standards for mineral project reporting, concerning the properties in question. "Leviathan Gold to acquire 100% interest in Botswanian copper and uranium assets" was originally created and published by Mining Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
